HealthTronics closes AMPI buy:
This article was originally published in Clinica
In a bid to diversify its urology product line, HealthTronics has bought urological cryosurgery specialist Advanced Medical Partners (AMPI) for an undisclosed fee. The deal saw HealthTronics pay a cash-and-stock mix to AMPI at the closing - AMPI will also receive performance-related earn-out payments. AMPI recorded revenues of over $24m in 2007. According to Austin, Texas-based HealthTronics, this acquisition will make it the largest provider of shock wave lithotripsy and cryosurgery services in the US. HealthTronics said it expects AMPI to provide top- and bottom- line synergies, thus enabling cost savings. In conjunction with the acquisition, HealthTronics also announced 2008 revenue guidance of $160-162m, and an operating profit target of $20-21m.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.